Recombinant pigeon pox virus vaccine
CA 2084064 A1 · Owner: Smithkline Beecham Corporation · Inventors: Carine, Letellier; Meulemans, Guy
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a recombinant pigeon pox virus synthetically modified by the presence in a non-essential region of, the pigeon pox genome of DNA not naturally occurring in pigeon pox virus. In a preferred embodiment of the invention pigeon pox, virus is modified by at least a portion of the Newcastle Disease virus F gene wherein the F gene is inserted within the thymidine kinase locus in the pigeon pox genome.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 1, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 1, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 1, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.